MINERALYS THERAPEUTICS, INC. Basic Shares Outstanding (Weighted Average)
MINERALYS THERAPEUTICS, INC. (MLYS) reported Basic Shares Outstanding (Weighted Average) of 84.73 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 84.73M shares, a 29.45% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 82.83M shares, a 55.81% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 81.22M shares, a 62.55% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 70.59M shares, a 41.71% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 67.66M shares, a 39.38% increase from fiscal 2024.
- MINERALYS THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 48.54M shares, a 34.13% increase from fiscal 2023.
- MINERALYS THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 36.19M shares, a 600.33% increase from fiscal 2022.
- MINERALYS THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 5.17M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 84.73M shares 10-Q · filed 2026-08-11 | 83.79M shares 10-Q · filed 2026-08-11 | 82.93M shares derived: average of 3 quarters · filed 2026-08-11 | 79.85M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 82.83M shares 10-Q · filed 2026-05-06 | 82.03M shares derived: average of 2 quarters · filed 2026-05-06 | 78.22M shares derived: average of 3 quarters · filed 2026-05-06 | 75.03M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | 81.22M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 75.91M shares derived: average of 2 quarters · filed 2026-03-12 | 72.42M shares derived: average of 3 quarters · filed 2026-08-11 | 67.66M shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 70.59M shares 10-Q · filed 2025-11-10 | 68.02M shares derived: average of 2 quarters · filed 2026-08-11 | 63.13M shares 10-Q · filed 2025-11-10 | 59.79M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | 65.45M shares 10-Q · filed 2026-08-11 | 59.34M shares 10-Q · filed 2026-08-11 | 56.19M shares derived: average of 3 quarters · filed 2026-08-11 | 54.60M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | 53.16M shares 10-Q · filed 2026-05-06 | 51.57M shares derived: average of 2 quarters · filed 2026-05-06 | 50.98M shares derived: average of 3 quarters · filed 2026-05-06 | 50.58M shares derived: average of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | 49.97M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 49.89M shares derived: average of 2 quarters · filed 2026-03-12 | 49.71M shares derived: average of 3 quarters · filed 2026-03-12 | 48.54M shares 10-K · filed 2026-03-12 |
| 2024-09-30 | 49.82M shares 10-Q · filed 2025-11-10 | 49.59M shares derived: average of 2 quarters · filed 2025-11-10 | 48.06M shares 10-Q · filed 2025-11-10 | 46.05M shares derived: average of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | 49.36M shares 10-Q · filed 2025-08-12 | 47.18M shares 10-Q · filed 2025-08-12 | 44.80M shares derived: average of 3 quarters · filed 2025-08-12 | 43.58M shares derived: average of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | 44.90M shares 10-Q · filed 2025-05-12 | 42.52M shares derived: average of 2 quarters · filed 2025-05-12 | 41.66M shares derived: average of 3 quarters · filed 2025-05-12 | 41.18M shares derived: average of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | 40.14M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | 40.03M shares derived: average of 2 quarters · filed 2025-02-12 | 39.94M shares derived: average of 3 quarters · filed 2025-02-12 | 36.19M shares 10-K · filed 2025-02-12 |
| 2023-09-30 | 39.93M shares 10-Q · filed 2024-11-12 | 39.84M shares derived: average of 2 quarters · filed 2024-11-12 | 34.87M shares 10-Q · filed 2024-11-12 | 27.42M shares derived: average of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | 39.75M shares 10-Q · filed 2024-08-13 | 32.30M shares 10-Q · filed 2024-08-13 | 23.24M shares derived: average of 3 quarters · filed 2024-08-13 | 18.73M shares derived: average of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | 24.76M shares 10-Q · filed 2024-05-09 | 14.99M shares derived: average of 2 quarters · filed 2024-05-09 | 11.72M shares derived: average of 3 quarters · filed 2024-05-09 | 10.08M shares derived: average of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | 5.21M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 5.20M shares derived: average of 2 quarters · filed 2024-03-21 | 5.18M shares derived: average of 3 quarters · filed 2024-03-21 | 5.17M shares 10-K · filed 2024-03-21 |
| 2022-09-30 | 5.18M shares 10-Q · filed 2023-11-07 | 5.17M shares derived: average of 2 quarters · filed 2023-11-07 | 5.15M shares 10-Q · filed 2023-11-07 | |
| 2022-06-30 | 5.15M shares 10-Q · filed 2023-08-07 | 5.14M shares 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | 5.12M shares 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |